SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Anticipation of Teslas Cybercab launch, reinforced by pedal-less vehicles being added to Texass robotaxi roster, is driving attention to TSLA. Traders are divided between optimism over robotaxi/FSD expansion and expectations of a short squeeze, and skepticism that the event is largely hype that could trigger a sell-the-news pullback.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of Vikings VK2735 maintenance-trial readout is driving attention, with traders focused on durable weight loss, efficacy, and tolerability as key validation for the obesity program. Bullish participants expect differentiated results to support a re-rating or potential partnership, while bearish traders question whether the data will exceed existing GLP-1 therapies and warn of sell-the-news pressure and dilution.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention around its monthly distribution announcement and payout, with traders celebrating the elevated income and discussing reinvestment strategies. The community is also debating whether the distribution is sustainable and noting that Nasdaq-linked volatility can support option premiums while limiting upside and pressuring the share price after the ex-dividend date.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

California lawmakers failure to include expected protections against wildfire-related claims has intensified concerns over Edison Internationals liability exposure, prompting analyst downgrades and a sharp selloff. Traders are divided between bears warning of prolonged legal, credit and dividend risk and bulls calling the decline an overreaction and buying the oversold dip.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

A broad Bitcoin-led crypto rally is driving attention to Coinbase as a high-beta proxy, with traders citing renewed momentum, a technical breakout, and potential short covering. Bullish participants expect the move to continue, while skeptics call it speculative and note that Coinbase has lagged Bitcoin and remains sensitive to interest-rate concerns.

Daily surprises, near and far. Your source for travel inspiration and more. Travel moves you!

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

The dominant catalyst is uncertainty over Paramount Skydances proposed acquisition of Warner Bros. Discovery after Californias attorney general canceled settlement talks amid the multistate antitrust case. Traders remain divided between expectations of a negotiated resolution and concerns that prolonged litigation could delay or derail the merger, increasing downside risk for WBD holders.

Corvex, Inc. is an AI cloud computing company, which specializes in GPU-accelerated infrastructure for AI workloads. Its products include GPU Clusters, Confidential Computing, Inference as a Service and GPU Node. The firm offers solutions include AI model builders, enterprises, federal and sovereign solutions. The company was founded by Seth Mitchell Demsey, Jay Crystal on October 21, 2024 and is headquartered in Arlington, VA.

Corvex Inc.

Movano Inc

A multi-year agreement for Corvex to provide NVIDIA Blackwell GPU clusters to an AI company, alongside planned data-center expansion, is driving attention and repositioning MOVE around an AI-infrastructure story. Traders are split between bullish expectations for momentum and a low-float short squeeze and concerns about the discounted financing, dilution risk, execution, and sharp post-pump fades.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Attention is centered on Keeta Personals rollout of ACH and multicurrency payment features alongside its Visa Direct partnership, which traders view as a potential fiat-to-blockchain payments catalyst. The community is broadly bullish, though skeptics question whether Visa is using Keetas network and whether meaningful transaction volume will follow, with the ASK Group UAE tokenization venture adding longer-term context.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

A recent quarterly report showing minimal revenue growth and declining policies-in-force has focused attention on Roots stalled growth strategy. Bulls emphasize continued profitability, cash generation, and the share-buyback program, while bears argue that reduced marketing spending supported earnings at the expense of customer growth and leaves the stock vulnerable to further weakness.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Exchange-listing momentum and heightened volume around Seekers Solana Mobile ecosystem are driving attention, with traders highlighting new access on major platforms and the tokens airdrop, staking, and phone-related utility. Bullish FOMO and short-squeeze speculation dominate, although some traders warn that free airdropped supply, staking unlocks, and sharp reversals could make the move a pump-and-dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Key PointsAdded 296,944 shares of Trevi Therapeutics; estimated buy value ~$3.32 million based on quarterly average price...

HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday...

Trevi Therapeutics Q1 Earnings Call Highlights

Trevi Therapeutics (NASDAQ:TRVI) management used the company's first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering.

Clinical program updates and upcoming trial starts
Pres...

Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07...

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI

Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...

TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening

Equity

The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?

Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...

Reported GAAP EPS of -$0.11 down -22.22% YoY

Trevi Therapeutics remains unprofitable with a growing accumulated deficit and faces intense competition from better-resourced pharmaceutical companies that could render the company's product development efforts obsolete or commercially noncompetitive.

Trevi Therapeutics is advancing its clinical pipeline with the initiation of Phase 3 trials for Haduvio and maintains a strong cash position to support development programs through at least 2030.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$16.60
Prev Close	$16.79
Open	$16.66
Dividend Yield	0.00%
50-Day Moving Average	$18.03
Beta	0.76
Avg. Volume	2.58M
PE Ratio	-48.99

52-Week High	$20.22
52-Week Low	$6.93
Market Capitalization	$2.39B
EPS (Annual)	-$0.3173
Price to Book	7.44
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info